RaQualia Pharma Inc. 4579.T Stock
RaQualia Pharma Inc. Price Chart
RaQualia Pharma Inc. 4579.T Financial and Trading Overview
RaQualia Pharma Inc. stock price | 535 JPY |
Previous Close | 758 JPY |
Open | 759 JPY |
Bid | 772 JPY x 0 |
Ask | 775 JPY x 0 |
Day's Range | 759 - 774 JPY |
52 Week Range | 643 - 1421 JPY |
Volume | 68.3K JPY |
Avg. Volume | 111.45K JPY |
Market Cap | 16.73B JPY |
Beta (5Y Monthly) | 0.865517 |
PE Ratio (TTM) | 23.229292 |
EPS (TTM) | -11.72 JPY |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
4579.T Valuation Measures
Enterprise Value | 12.94B JPY |
Trailing P/E | 23.229292 |
Forward P/E | 18.516747 |
PEG Ratio (5 yr expected) | N/A |
Price/Sales (ttm) | 5.673559 |
Price/Book (mrq) | 2.6752663 |
Enterprise Value/Revenue | 4.387 |
Enterprise Value/EBITDA | 12.633 |
Trading Information
RaQualia Pharma Inc. Stock Price History
Beta (5Y Monthly) | 0.865517 |
52-Week Change | 13.47% |
S&P500 52-Week Change | 20.43% |
52 Week High | 1421 JPY |
52 Week Low | 643 JPY |
50-Day Moving Average | 808.86 JPY |
200-Day Moving Average | 1015.85 JPY |
4579.T Share Statistics
Avg. Volume (3 month) | 111.45K JPY |
Avg. Daily Volume (10-Days) | 124.69K JPY |
Shares Outstanding | 21.62M |
Float | 17.01M |
Short Ratio | N/A |
% Held by Insiders | 16.75% |
% Held by Institutions | 11.85% |
Shares Short | N/A |
Short % of Float | N/A |
Short % of Shares Outstanding | N/A |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | March 31, 2023 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | 23.56% |
Operating Margin (ttm) | 29.77% |
Gross Margin | 99.79% |
EBITDA Margin | 34.72% |
Management Effectiveness
Return on Assets (ttm) | 9.03% |
Return on Equity (ttm) | 12.73% |
Income Statement
Revenue (ttm) | 2.95B JPY |
Revenue Per Share (ttm) | 139.61 JPY |
Quarterly Revenue Growth (yoy) | 9.09% |
Gross Profit (ttm) | 2.92B JPY |
EBITDA | 1.02B JPY |
Net Income Avi to Common (ttm) | 695M JPY |
Diluted EPS (ttm) | 33.32 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 4.53B JPY |
Total Cash Per Share (mrq) | 209.56 JPY |
Total Debt (mrq) | 259M JPY |
Total Debt/Equity (mrq) | 4.14 JPY |
Current Ratio (mrq) | 14.115 |
Book Value Per Share (mrq) | 289.317 |
Cash Flow Statement
Operating Cash Flow (ttm) | 898M JPY |
Levered Free Cash Flow (ttm) | 673.75M JPY |
Profile of RaQualia Pharma Inc.
Country | Japan |
State | N/A |
City | Nagoya |
Address | Meieki Southside Square |
ZIP | 450-0003 |
Phone | 81 52 446 6100 |
Website | https://www.raqualia.co.jp |
Industry | Biotechnology |
Sector(s) | Healthcare |
Full Time Employees | 65 |
RaQualia Pharma Inc. engages in the research and development of pharmaceutical compounds worldwide. Its human products portfolio includes tegoprazan for gastroesophageal reflux disease, which is in phase 1 clinical trial in the United States; and grapiprant for pain management, which is in phase II clinical trial in the United States and phase I clinical trial in China, as well as in phase I clinical trial in China and the United States to treat cancer. The company also provides veterinary products such as, grapiprant for osteoarthritis in dogs; ghrelin receptor agonist to treat cancer-related anorexia/cachexia syndrome, and constipation resulting from spinal cord injury; and ELURA, a drug for the management of weight loss in cats with chronic kidney disease. In addition, it provides TRPM8 blocker for the target indication of neuropathic pain; motilin receptor agonist to treat gastrointestinal dysmotility, including gastroparesis, functional dyspepsia, and post-operative ileus; potassium-competitive acid blocker to treat gastro-esophageal reflux disease that has completed phase 1 clinical trial; 5-HT4 partial agonist to treat gastroparesis, functional dyspepsia, and chronic constipation; 5-HT2B antagonist to treat irritable bowel syndrome with diarrhea; EP4 antagonist, a pain management drugs for dogs; serotonin 5-HT2A and dopamine D2 receptor blocker to treat schizophrenia; EP4 antagonist to treat cancer that is in phase I clinical trial, as well as in phase 1 clinical trial for the indication of pain; Cyclooxygenase-2 inhibitor, Phase I clinical trials for the indication of pain; CB2 agonist; selective sodium channel blocker; P2X7 receptor antagonist, which is in Phase I clinical trials for the target indication of neuropathic pain; and retinoic acid receptor alpha agonist. It has a collaborative agreement with Interprotein Corporation, ASKA Pharmaceutical. Co., Ltd., and Epigeneron, Inc. The company was incorporated in 2008 and is headquartered in Nagoya, Japan.
Q&A For RaQualia Pharma Inc. Stock
What is a current 4579.T stock price?
RaQualia Pharma Inc. 4579.T stock price today per share is 535 JPY.
How to purchase RaQualia Pharma Inc. stock?
You can buy 4579.T shares on the Tokyo exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for RaQualia Pharma Inc.?
The stock symbol or ticker of RaQualia Pharma Inc. is 4579.T.
Which industry does the RaQualia Pharma Inc. company belong to?
The RaQualia Pharma Inc. industry is Biotechnology.
How many shares does RaQualia Pharma Inc. have in circulation?
The max supply of RaQualia Pharma Inc. shares is 21.64M.
What is RaQualia Pharma Inc. Price to Earnings Ratio (PE Ratio)?
RaQualia Pharma Inc. PE Ratio is now.
What was RaQualia Pharma Inc. earnings per share over the trailing 12 months (TTM)?
RaQualia Pharma Inc. EPS is -11.72 JPY over the trailing 12 months.
Which sector does the RaQualia Pharma Inc. company belong to?
The RaQualia Pharma Inc. sector is Healthcare.